Divalproex sodium: Migraine treatment and monitoring

Headache

Volumn 36, Issue 4, 1996, Pages 239-242

  Silberstein, Stephen D ^a,c   James Wilmore, L ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Germantown Hospital   (United States)

Author keywords

divalproex sodium; hepatotoxicity; migraine

Indexed keywords

VALPROATE SEMISODIUM;

ACIDURIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HAIR LOSS; HUMAN; INFANT; LIVER TOXICITY; METABOLIC DISORDER; MIGRAINE; PANCREATITIS; PRIORITY JOURNAL; TREMOR; WEIGHT GAIN;

EID: 9344247444     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.1996.3604239.x     Document Type: Article

References (28)

1. Physicians' Desk Reference. 49th ed. Oradell, NJ: Medical Economics Company; 1995.
2. Bourgeois FD. Valproic acid. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. 4th ed. New York: Raven Press; 1995;633-639.
3. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a tripleblind, placebo-controlled crossover study. Neurology. 1994;44:647-651.
4. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52: 281-286.
5. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-bund study versus placebo. Cephalalgia. 1992;12:81-84.
6. Klapper J. Divalproex sodium in the prophylactic treatment of migraine. Headache. 1995;35:290. Abstract.
7. Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache. An open label study. Headache. 1991;31:71-74.
8. Hering R, Kuritzky A. Sodium valproate in the treatment of cluster headache: an open clinical trial. Cephalalgia. 1989;9:195-198.
9. DeVries SI. Hematologic aspects during treatment with anticonvulsant drugs. Epilepsia. 1965;6:1-15.
10. Krogh CM, ed. Compendium of Pharmaceuticals and Specialties. 25th ed. Canada: Canadian Pharmaceutical Association; 1990.
11. Pellock JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology. 1991;41:961-964.
12. Pellock JM, Pippenger CE. Adverse effects of antiepileptic drugs. In: Dodson EW, Padlock JM, eds. Pediatric Epilepsy Diagnosis and Therapy. New York: Demos Publications. In press.
13. Kutt H. Therapeutic monitoring of antiepileptic drugs. In: Pedley TA, Meldrum BS, eds. Recent Advances in Epilepsy II. New York: Churchill Livingstone; 1985.
14. Dodson WE. Level off. Neurology. 1989;39:1009-1010.
15. Driefuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB, Valproic acid hepatic fatalities: a retrospective review. Neurology. 1987;37:379-385.
16. Driefuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities. II. US experience since 1984. Neurology. 1989;39:201-207.
17. Willmore LJ, Triggs WJ, Pellock JM. Valproate toxicity: risk-screening strategies. J Child Neurol. 1991;6:3-6.
18. Gerber N, Dickinson RG, Harland RC, et al. Reye-like syndrome associated with valproic acid therapy. J Pediatr. 1979;95:142-144.
19. van Egmond H, Degomme P, de Simpel H, Dierick AM, Roels H. A suspected case of late-onset sodiumvalproate-induced hepatic failure. Neuropediatrics. 1987;18:96-98.
20. Kuhara T, Inoue Y, Matsumoto M, et al. Markedly increased omega-oxidation of valproate in fulminant hepatic failure. Epilepsia. 1990;31:214-217.
21. Schaffner D, Konig S, Rauterberg-Ruland I, Kochen W, Hofmann WJ, Unkelbach S. Fatal liver failure in 16 children with valproate therapy. Epilepsia. 1988;29:530-542.
22. Jellinger K, Seitelberger F. Spongy encephaiopathies in infancy: spongy degeneration of CNS and progressive infantile poliodystrophy. In: Goldensohn ES, Appel SA, eds. Scientific Approaches to Clinical Neurology. Philadelphia: Lea & Febiger; 1977;363.
23. 3 in muscle: a report of two unrelated patients. Clin Neurol Neurosurg. 1972;85-87.
24. Prick M, Gabreels F, Renier W, et al. Pyruvate dehydrogenase deficiency restricted to brain. Neurology. 1981;31:398-404.
25. Zimmerman HJ. Ishak KG. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology. 1982;2:591-597.
26. Berkovic SF, Bladin PF, Jones DB, Smallwood RA, Vajda FJ. Hepatotoxicity of sodium valproate. Clin Exp Neurol. 1983;19:192-197.
27. Rettie AE, Rettenmeier AW, Howald WN, Baillie TA. Cytochrome P-450-catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science. 1987;235: 890-893.
28. Camfield C, Camfield P, Smith E, Tibbles JA. Asymptomatic children with epilepsy: little benefit from screening for anticonvulsant-induced liver, blood, or renal damage. Neurology. 1986;36:838-841.